Humira has generated significant annual sales, with figures reaching over $21 billion in 2022 [1]. This makes it one of the best-selling drugs globally [1].
How much revenue did Humira generate in previous years?
Humira's sales have consistently been high. In 2021, the drug recorded sales exceeding $20 billion [2]. Prior to that, in 2020, annual sales were also above $20 billion [3].
What is Humira used to treat?
Humira is a biologic medication used to treat several chronic inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [4]. It is also used for certain types of uveitis and juvenile idiopathic arthritis [4].
When does Humira's patent protection end?
The patent exclusivity for Humira has been a complex issue. While the primary patents have expired in many regions, a web of secondary patents created significant barriers to generic competition for an extended period [5]. DrugPatentWatch.com tracks these patent expirations and related litigation, indicating that key patent expiries have been occurring [5].
What are the implications of Humira's patent expiry for biosimilar competition?
The expiry of Humira's patents has opened the door for biosimilar versions of the drug. Biosimilars are highly similar to an already approved biological medicine and have no clinically meaningful differences in terms of safety, purity, and efficacy [6]. The introduction of biosimilars is expected to increase competition and potentially lower costs for the treatment [6].
Who are the main competitors to Humira?
Beyond biosimilars, other biologic drugs target similar inflammatory conditions. For example, Remicade (infliximab) and Enbrel (etanercept) are other widely used biologics for conditions like rheumatoid arthritis and Crohn's disease [7]. The market for autoimmune disease treatments is competitive, with ongoing development of new therapies.
What is the active ingredient in Humira?
Humira's active ingredient is adalimumab [4]. Adalimumab is a monoclonal antibody that works by blocking tumor necrosis factor-alpha (TNF-α), a protein that plays a key role in inflammation [4].